Compounds > pimozide
Page last updated: 2024-08-22

pimozide and ziprasidone

pimozide has been researched along with ziprasidone in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (13.33)18.2507
2000's9 (60.00)29.6817
2010's4 (26.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L1
Chen, XL; Kang, J; Kongsamut, S; Rampe, D; Roehr, J1
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M1
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S1
Li, J; Rajamani, R; Reynolds, CH; Tounge, BA1
Nagashima, R; Nishikawa, T; Tobita, M1
Andricopulo, AD; Moda, TL; Montanari, CA1
Jia, L; Sun, H1
Caron, G; Ermondi, G; Visentin, S1
Giordanetto, F; Leach, AG; Zachariae, U1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A1
Sen, S; Sinha, N1
Andreasson, T; Mattsson, C; Sonesson, C; Waters, N1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Blakely, RD; Jansen, K; Richelson, E; Tatsumi, M1

Reviews

1 review(s) available for pimozide and ziprasidone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

14 other study(ies) available for pimozide and ziprasidone

ArticleYear
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
    European journal of pharmacology, 1998, Aug-21, Volume: 355, Issue:2-3

    Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes

1998
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
    European journal of pharmacology, 2002, Aug-16, Volume: 450, Issue:1

    Topics: Animals; Antipsychotic Agents; Cation Transport Proteins; Cell Line; Clinical Trials as Topic; Cricetinae; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Trans-Activators; Transcriptional Regulator ERG

2002
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
    Journal of medicinal chemistry, 2002, Aug-29, Volume: 45, Issue:18

    Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2002
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3

    Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain

2003
A two-state homology model of the hERG K+ channel: application to ligand binding.
    Bioorganic & medicinal chemistry letters, 2005, Mar-15, Volume: 15, Issue:6

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation

2005
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:5

    Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship

2009
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14

    Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation

2009
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics

2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Locomotion; Molecular Structure; Psychotic Disorders; Rats; Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship

2012
Pharmacological profile of neuroleptics at human monoamine transporters.
    European journal of pharmacology, 1999, Mar-05, Volume: 368, Issue:2-3

    Topics: Antipsychotic Agents; Carrier Proteins; Cell Line; Chlorpromazine; Cocaine; Dibenzazepines; Dibenzothiepins; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Humans; Imipramine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Pimozide; Piperazines; Protein Binding; Radioligand Assay; Recombinant Fusion Proteins; Serotonin Plasma Membrane Transport Proteins; Symporters; Thiazoles; Triflupromazine; Tritium

1999